Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione Policlinico Universitario A. Gemelli IRCCS have discovered that by inhibiting the ...

Brian Percival's film, set in 1938, follows a young girl who a German family adopted during the Nazi was taught to read by ...

The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Many of us wonder how to slow down or completely stop the progression of Alzheimer's disease. It's often regarded as a ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

TAMPA — November marks National Alzheimer’s Disease Awareness Month. According to the Alzheimer’s Association, nearly 7 ...

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for ...